

Expert committees and study groups

Expert advisory panels and committees and their membership

Report by the Secretariat¹

ESTABLISHMENT OR DISESTABLISHMENT OF EXPERT ADVISORY PANELS

1. No change has occurred during 2006.

MEMBERSHIP OF THE EXPERT ADVISORY PANELS

2. Membership of the 52 expert advisory panels totalled 734 in December 2006, compared with 793 in December 2005. Of the regional distribution of all members of all panels, 9% come from the African Region, 23% from the Region of the Americas, 9% from the South-East Asia Region, 35% from the European Region, 11% from the Eastern Mediterranean Region and 13% from the Western Pacific Region. Of the total of all members of all panels, 23% are women.
3. A list of all panels is annexed, which includes a breakdown of members by panel, Region and sex, as of December 2006. An alphabetical list of experts giving nationality is available to members of the Board on request.

MEETINGS OF EXPERT COMMITTEES

4. The following committees met in 2006:

Expert Committee on Drug Dependence (34th meeting), Geneva, 28–31 March 2006
(seven WHO members: four men, three women)

Expert Committee on Specifications for Pharmaceutical Preparations (41st meeting), Geneva,
16–20 October 2006 (nine WHO members: five men, four women)

¹ This report is submitted to the Executive Board in compliance with regulation 4.23 of the Regulations for Expert Advisory Panels and Committees.

Advisory Committee on Health Research, (46th meeting), Geneva, 24–26 April 2006 (nine WHO members: six men, three women)

Joint FAO/WHO Expert Committee on Food Additives, (66th meeting) Rome, 22–28 February 2006 (five WHO members: five men); (67th meeting) Rome, 20–29 June 2006 (seven members: five men, two women)

Expert Committee on Biological Standardization, Geneva, 23–27 October 2006 (10 members: eight men, two women)

Expert Committee on Problems Related to Alcohol Consumption, Geneva, 10–13 October 2006 (11 members: six men, five women)

5. Invitations to take part in these meetings were extended to 58 panel members (one member was unable to attend) from 30 different countries, drawn from eight expert advisory panels.

ANNEX

MEMBERSHIP OF WHO EXPERT ADVISORY PANELS BY PANEL AND REGION

| WHO expert advisory panels | Africa | | The Americas | | South-East Asia | | Europe | | Eastern Mediterranean | | Western Pacific | | Total | | |
|---|--------|---|--------------|---|-----------------|---|--------|---|-----------------------|---|-----------------|---|-------|----|-----|
| | N | W | N | W | N | W | N | W | N | W | N | W | N | W | % |
| Acute bacterial diseases | 0 | 0 | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 |
| Acute diarrhoeal diseases and other enteric infections | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 50 |
| Ageing and health | 2 | 2 | 4 | 3 | 1 | 0 | 9 | 2 | 2 | 1 | 0 | 0 | 18 | 8 | 44 |
| Biological standardization | 0 | 0 | 7 | 1 | 3 | 1 | 13 | 2 | 2 | 1 | 5 | 1 | 30 | 6 | 20 |
| Blood transfusion medicine | 6 | 1 | 2 | 1 | 1 | 1 | 5 | 1 | 3 | 2 | 2 | 1 | 19 | 7 | 37 |
| Cancer | 0 | 0 | 9 | 2 | 1 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 14 | 2 | 14 |
| Cardiovascular diseases | 2 | 0 | 3 | 0 | 2 | 0 | 6 | 0 | 3 | 0 | 4 | 0 | 20 | 0 | 0 |
| Chronic degenerative diseases (diabetes) | 2 | 0 | 3 | 0 | 1 | 1 | 6 | 0 | 1 | 0 | 2 | 0 | 15 | 1 | 7 |
| Chronic degenerative diseases (rheumatic diseases) | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 33 |
| Clinical surgical procedures | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 6 | 0 | 0 |
| Development of human resources for health | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Drug dependence (dependence liability evaluation) | 0 | 0 | 5 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 4 | 1 | 13 | 2 | 15 |
| Drug dependence and alcohol problems | 1 | 0 | 5 | 2 | 3 | 1 | 10 | 3 | 2 | 0 | 6 | 1 | 27 | 7 | 26 |
| Drug evaluation | 4 | 1 | 6 | 2 | 5 | 4 | 7 | 4 | 5 | 1 | 4 | 2 | 31 | 14 | 45 |
| Drug policies and management | 3 | 2 | 3 | 1 | 3 | 2 | 10 | 6 | 2 | 0 | 6 | 3 | 27 | 14 | 52 |
| Food safety | 1 | 0 | 14 | 5 | 2 | 1 | 13 | 1 | 0 | 0 | 6 | 0 | 36 | 7 | 19 |
| Health laboratory services | 3 | 0 | 4 | 1 | 0 | 0 | 7 | 2 | 5 | 2 | 1 | 1 | 20 | 6 | 30 |
| Health promotion and education | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 100 |
| Health science and technology policy | 5 | 3 | 4 | 2 | 2 | 1 | 5 | 1 | 3 | 1 | 4 | 2 | 23 | 10 | 43 |
| Human cell, tissue and organ transplanation | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 0 | 0 |
| Human genetics | 2 | 0 | 6 | 1 | 2 | 0 | 11 | 2 | 2 | 1 | 1 | 0 | 24 | 4 | 17 |
| Human reproduction | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 33 |
| Immunology | 0 | 0 | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 7 | 0 | 0 |
| Injury and violence prevention and control | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| International pharmacopoeia and pharmaceutical preparations | 8 | 0 | 11 | 8 | 2 | 2 | 27 | 9 | 9 | 3 | 10 | 1 | 67 | 23 | 34 |
| Leprosy | 0 | 0 | 2 | 0 | 4 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 10 | 0 | 0 |

| WHO expert advisory panels | Africa | | The Americas | | South-East Asia | | Europe | | Eastern Mediterranean | | Western Pacific | | Total | | |
|---|--------|-----|--------------|-----|-----------------|-----|--------|-----|-----------------------|-----|-----------------|-----|-------|-----|-----|
| | N | W | N | W | N | W | N | W | N | W | N | W | N | W | % |
| Malaria | 1 | 0 | 2 | 0 | 2 | 0 | 11 | 0 | 2 | 0 | 0 | 0 | 18 | 0 | 0 |
| Maternal and child health | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 5 | 2 | 40 |
| Mental health | 0 | 0 | 6 | 0 | 3 | 2 | 15 | 2 | 2 | 0 | 3 | 1 | 29 | 5 | 17 |
| Neurosciences | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 33 |
| Nursing | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 3 | 3 | 1 | 1 | 8 | 8 | 100 |
| Nutrition | 0 | 0 | 5 | 0 | 2 | 1 | 3 | 1 | 5 | 2 | 3 | 0 | 18 | 4 | 22 |
| Oral health | 2 | 0 | 1 | 0 | 3 | 1 | 9 | 1 | 2 | 0 | 2 | 0 | 19 | 2 | 11 |
| Parasitic diseases (filarial infections) | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Parasitic diseases (general parasitology) | 3 | 0 | 7 | 3 | 2 | 1 | 12 | 2 | 2 | 0 | 3 | 0 | 29 | 6 | 21 |
| Parasitic diseases (leishmaniasis) | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 |
| Parasitic diseases (schistosomiasis) | 2 | 0 | 7 | 0 | 0 | 0 | 8 | 0 | 3 | 1 | 6 | 0 | 26 | 1 | 4 |
| Parasitic diseases (trypanosomiasis) | 1 | 0 | 9 | 5 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 15 | 5 | 33 |
| Prevention of blindness | 1 | 1 | 5 | 2 | 0 | 0 | 3 | 0 | 2 | 0 | 4 | 0 | 15 | 3 | 20 |
| Prevention of deafness and hearing impairment | 0 | 0 | 3 | 0 | 1 | 1 | 4 | 1 | 1 | 0 | 2 | 0 | 11 | 2 | 18 |
| Rabies | 1 | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 8 | 0 | 0 |
| Radiation | 0 | 0 | 2 | 1 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 6 | 1 | 17 |
| Rehabilitation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Respiratory infections | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Sexually transmitted infections including those due to human immunodeficiency virus | 1 | 0 | 3 | 1 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 8 | 2 | 25 |
| Traditional medicine | 2 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 7 | 2 | 29 |
| Tuberculosis | 4 | 2 | 6 | 1 | 2 | 0 | 5 | 2 | 2 | 1 | 5 | 1 | 24 | 7 | 29 |
| Vector biology and control | 2 | 0 | 3 | 0 | 4 | 2 | 12 | 2 | 2 | 0 | 6 | 1 | 29 | 5 | 17 |
| Virus diseases | 1 | 0 | 2 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 17 |
| Virus diseases (antivirals and interferon) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Zoonoses | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 |
| Total | 62 | 12 | 171 | 45 | 69 | 27 | 256 | 47 | 79 | 22 | 97 | 19 | 734 | 172 | 23 |
| | | 19% | | 26% | | 39% | | 18% | | 18% | | 20% | | | |

Number of panel members as of December 2006 where N denotes total number of panel members, W the number of women members, and % the percentage of women panel members by panel and region.